1. < Hematology/Oncology

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study

By sjmartinez • March 9, 2023

Johnson ML, Strauss J, Patel MR, Garon EB, Eaton KD, Neskorik T, Morin J, Chao R, Halmos B. Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study. Clin Lung Cancer. 2023 Feb 8:S1525-7304(23)00012-8. doi: 10.1016/j.cllc.2023.01.013. Epub ahead of print. PMID: 36890020.

Tags: Checkpoint Inhibitor, HDAC, Hematology/Oncology, Histone deacetylase inhibitor, PD­L1, Programmed death-ligand 1, Publications

Related Posts

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC,[...]

A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning

Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, Travisano KA, Filsinger Interrante MV, Bruun TUJ, Rezek V, Wilder B, Palomares M,[...]

Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

Krebs MG, Cho BC, Hiret S, Han JY, Lee KH, Llácer Pérez C, De Braud F, Haura EB, Sanborn RE, Yang JC, Shu CA, Goto[...]